Shionogi's novel obesity drug velneperit shows Phase II promise
This article was originally published in Scrip
Executive Summary
Shionogi has announced positive results from two separate Phase II trials of its novel oral neuropeptide Y (NPY) Y5 receptor antagonist, velneperit (S-2367), which demonstrated a reduction in body weight in clinically obese patients.